Biotech IPO wave rolls on as Werewolf, Vaccitech raise $230M for clinical trials
Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines.